VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

被引:115
作者
Burstein, Harold J. [1 ]
Chen, Yu-Hui [1 ]
Parker, Leroy M. [1 ]
Savoie, Jennifer [1 ]
Younger, Jerry [2 ]
Kuter, Irene [2 ]
Ryan, Paula D. [2 ]
Garber, Judy E. [1 ]
Chen, Helen [4 ]
Campos, Susana M. [1 ]
Shulman, Lawrence N. [1 ]
Harris, Lyndsay N. [3 ]
Gelman, Rebecca [1 ]
Winer, Eric P. [1 ]
机构
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[3] Natl Canc Inst, Bethesda, MD USA
[4] Yale Univ, Sch Med, New Haven, CT USA
关键词
D O I
10.1158/1078-0432.CCR-08-0593
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Anti-vascular endothelial growth factor therapy (VEGF) is an important new treatment modality in oncology.We sought to determine the efficacy and safety of the humanized monoclonal anti-VEGF antibody, bevacizumab, and vinorelbine as treatment for refractory breast cancer and to explore the role of plasma VEGF as a predictor of treatment outcome. Experimental Design: Eligible patients had received one or two prior chemotherapy regimens for metastatic breast cancer or recurred within 12 months of adjuvant therapy and had measurable disease and adequate end-organ function. Patients received bevacizumab 10 mg/kg every 2 weeks, and vinorelbine each week, until tumor progression or prohibitive toxicity. Plasma VEGF was measured at baseline. Results: Among 56 women treated on protocol, bevacizumab and vinorelbine yielded a 34% response rate (95% confidence interval, 22-48%) and median time to progression of 5.5 months. Activity was observed regardless of tumor hormone receptor status or type or extent of prior chemotherapy. Side effects included uncomplicated neutropenia, hypertension, nasal congestion/epistaxis, and neuropathy, consistent with well-described side effects of the respective agents. Three patients had impaired wound healing following surgical procedures. There were only rare instances of thrombosis or clinically significant proteinuria. Lower levels of baseline VEGF were associated with longer time to progression. Conclusions: Bevacizumab and vinorelbine are well tolerated and effective as treatment for refractory breast cancer. Plasma VEGF warrants further evaluation as a prognostic marker for treatment outcome in advanced breast cancer patients receiving anti-VEGF therapy.
引用
收藏
页码:7871 / 7877
页数:7
相关论文
共 18 条
[1]   Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm [J].
Burstein, HJ ;
Harris, LN ;
Marcom, PK ;
Lambert-Falls, R ;
Havlin, K ;
Overmoyer, B ;
Friedlander, RJ ;
Gargiulo, J ;
Strenger, R ;
Vogel, CL ;
Ryan, PD ;
Ellis, MJ ;
Nunes, RA ;
Bunnell, CA ;
Campos, SM ;
Hallor, M ;
Gelman, R ;
Winer, EP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2889-2895
[2]   A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer [J].
Cobleigh, MA ;
Langmuir, VK ;
Sledge, GW ;
Miller, KD ;
Haney, L ;
Novotny, WF ;
Reimann, JD ;
Vassel, A .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :117-124
[3]   Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia [J].
Garcia, Agustin A. ;
Hirte, Hal ;
Fleming, Gini ;
Yang, Dongyun ;
Tsao-Wei, Denice D. ;
Roman, Lynda ;
Groshen, Susan ;
Swenson, Steve ;
Markland, Frank ;
Gandara, David ;
Scudder, Sidney ;
Morgan, Robert ;
Chen, Helen ;
Lenz, Heinz-Josef ;
Oza, Amit M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :76-82
[4]   Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma [J].
Gasparini, G ;
Toi, M ;
Gion, M ;
Verderio, P ;
Dittadi, R ;
Hanatani, M ;
Matsubara, I ;
Vinante, O ;
Bonoldi, E ;
Boracchi, P ;
Gatti, C ;
Suzuki, H ;
Tominaga, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (02) :139-147
[5]   Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J].
Hicklin, DJ ;
Ellis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1011-1027
[6]  
HOLDEN SN, 2005, J CLIN ONCOL S, V23
[7]   Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development [J].
Kruczynski, Anna ;
Poli, Maura ;
Dossi, Romina ;
Chazottes, Eric ;
Berrichon, Geraldine ;
Ricome, Christel ;
Giavazzi, Raffaella ;
Hill, Bridget T. ;
Taraboletti, Giulia .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (16) :2821-2832
[8]   Chemotherapy for metastatic breast cancer [J].
Mayer, Erica L. ;
Burstein, Harold J. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) :257-+
[9]   Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].
Miller, Kathy ;
Wang, Molin ;
Gralow, Julie ;
Dickler, Maura ;
Cobleigh, Melody ;
Perez, Edith A. ;
Shenkier, Tamara ;
Cella, David ;
Davidson, Nancy E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676
[10]   Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J].
Miller, KD ;
Chap, LI ;
Holmes, FA ;
Cobleigh, MA ;
Marcom, PK ;
Fehrenbacher, L ;
Dickler, M ;
Overmoyer, BA ;
Reimann, JD ;
Sing, AP ;
Langmuir, V ;
Rugo, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :792-799